117 related articles for article (PubMed ID: 7574268)
21. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia.
Lee J; Zhu WM; Stanic D; Finkelstein DI; Horne MH; Henderson J; Lawrence AJ; O'Connor L; Tomas D; Drago J; Horne MK
Brain; 2008 Jun; 131(Pt 6):1574-87. PubMed ID: 18487277
[TBL] [Abstract][Full Text] [Related]
22. Neuronal pathology in Parkinson's disease.
Schulz JB; Falkenburger BH
Cell Tissue Res; 2004 Oct; 318(1):135-47. PubMed ID: 15365812
[TBL] [Abstract][Full Text] [Related]
23. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.
Porritt MJ; Batchelor PE; Howells DW
Exp Neurol; 2005 Mar; 192(1):226-34. PubMed ID: 15698637
[TBL] [Abstract][Full Text] [Related]
24. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease.
Anglade P; Vyas S; Javoy-Agid F; Herrero MT; Michel PP; Marquez J; Mouatt-Prigent A; Ruberg M; Hirsch EC; Agid Y
Histol Histopathol; 1997 Jan; 12(1):25-31. PubMed ID: 9046040
[TBL] [Abstract][Full Text] [Related]
25. Participation of prostate apoptosis response-4 in degeneration of dopaminergic neurons in models of Parkinson's disease.
Duan W; Zhang Z; Gash DM; Mattson MP
Ann Neurol; 1999 Oct; 46(4):587-97. PubMed ID: 10514095
[TBL] [Abstract][Full Text] [Related]
26. Dopamine and adult neurogenesis.
Borta A; Höglinger GU
J Neurochem; 2007 Feb; 100(3):587-95. PubMed ID: 17101030
[TBL] [Abstract][Full Text] [Related]
27. Dopamine complexes of iron in the etiology and pathogenesis of Parkinson's disease.
Arreguin S; Nelson P; Padway S; Shirazi M; Pierpont C
J Inorg Biochem; 2009 Jan; 103(1):87-93. PubMed ID: 18976814
[TBL] [Abstract][Full Text] [Related]
28. alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease.
Sidhu A; Wersinger C; Vernier P
FEBS Lett; 2004 May; 565(1-3):1-5. PubMed ID: 15135042
[TBL] [Abstract][Full Text] [Related]
29. Gender differences in neurotoxicity of the nigrostriatal dopaminergic system: implications for Parkinson's disease.
Dluzen DE; McDermott JL
J Gend Specif Med; 2000; 3(6):36-42. PubMed ID: 11253381
[TBL] [Abstract][Full Text] [Related]
30. The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
Exp Neurol; 2004 Jul; 188(1):65-73. PubMed ID: 15191803
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease.
Watanabe Y; Himeda T; Araki T
Med Sci Monit; 2005 Jan; 11(1):RA17-23. PubMed ID: 15614202
[TBL] [Abstract][Full Text] [Related]
32. Striatal neuroadaptation and rescue of locomotor deficit by L-dopa in aphakia mice, a model of Parkinson's disease.
van den Munckhof P; Gilbert F; Chamberland M; Lévesque D; Drouin J
J Neurochem; 2006 Jan; 96(1):160-70. PubMed ID: 16269007
[TBL] [Abstract][Full Text] [Related]
33. Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease.
McRitchie DA; Cartwright HR; Halliday GM
Exp Neurol; 1997 Mar; 144(1):202-13. PubMed ID: 9126172
[TBL] [Abstract][Full Text] [Related]
34. Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
Srinivasan J; Schmidt WJ
Behav Brain Res; 2004 May; 151(1-2):191-9. PubMed ID: 15084435
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms of Parkinson's disease.
Br Med J; 1978 Apr; 1(6117):872-3. PubMed ID: 25109
[No Abstract] [Full Text] [Related]
36. Biomarkers, mechanisms, and potential prevention of catecholamine neuron loss in Parkinson disease.
Goldstein DS
Adv Pharmacol; 2013; 68():235-72. PubMed ID: 24054148
[TBL] [Abstract][Full Text] [Related]
37. Dopaminergic regulation of cholinergic neurons in the striatum: relation to Parkinsonism.
Bartholini G; Lloyd KG; Stadler H
Adv Neurol; 1974; 5():11-4. PubMed ID: 4440567
[No Abstract] [Full Text] [Related]
38. Serotonergic-dopaminergic interactions and extrapyramidal function.
Chase TN
Adv Biochem Psychopharmacol; 1974; 11(0):377-85. PubMed ID: 4367649
[No Abstract] [Full Text] [Related]
39. Behavioral disorders in Parkinson's disease: the role of dopamine.
Antonelli F; Strafella AP
Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S10-2. PubMed ID: 24262157
[TBL] [Abstract][Full Text] [Related]
40. Preclinical markers in studies of Parkinson's disease.
Ellenberg JH
Geriatrics; 1991 Aug; 46 Suppl 1():16-24. PubMed ID: 1894141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
